168 related articles for article (PubMed ID: 30317148)
1. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients.
Degeling K; Franken MD; May AM; van Oijen MGH; Koopman M; Punt CJA; IJzerman MJ; Koffijberg H
Cancer Epidemiol; 2018 Dec; 57():60-67. PubMed ID: 30317148
[TBL] [Abstract][Full Text] [Related]
2. An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting.
Standfield LB; Comans TA; Scuffham PA
Eur J Health Econ; 2017 Jan; 18(1):33-47. PubMed ID: 26715578
[TBL] [Abstract][Full Text] [Related]
3. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
Noon KM; Montgomery SM; Adlard NE; Kroes MA
J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
[TBL] [Abstract][Full Text] [Related]
4. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.
Williams C; Lewsey JD; Mackay DF; Briggs AH
Med Decis Making; 2017 May; 37(4):427-439. PubMed ID: 27698003
[TBL] [Abstract][Full Text] [Related]
5. Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness.
Jahn B; Kurzthaler C; Chhatwal J; Elbasha EH; Conrads-Frank A; Rochau U; Sroczynski G; Urach C; Bundo M; Popper N; Siebert U
Med Decis Making; 2019 Jul; 39(5):509-522. PubMed ID: 31253053
[No Abstract] [Full Text] [Related]
6. Markov modeling and discrete event simulation in health care: a systematic comparison.
Standfield L; Comans T; Scuffham P
Int J Technol Assess Health Care; 2014 Apr; 30(2):165-72. PubMed ID: 24774101
[TBL] [Abstract][Full Text] [Related]
7. Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.
Jahn B; Rochau U; Kurzthaler C; Paulden M; Kluibenschädl M; Arvandi M; Kühne F; Goehler A; Krahn MD; Siebert U
Med Decis Making; 2016 Apr; 36(3):375-90. PubMed ID: 26476865
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model.
Castelli C; Combescure C; Foucher Y; Daures JP
Stat Med; 2007 Dec; 26(30):5557-71. PubMed ID: 18058847
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Cho SK; Hay JW; Barzi A
Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
[TBL] [Abstract][Full Text] [Related]
10. Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer.
Degeling K; IJzerman MJ; Groothuis-Oudshoorn CGM; Franken MD; Koopman M; Clements MS; Koffijberg H
Value Health; 2022 Jan; 25(1):104-115. PubMed ID: 35031089
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
Franken MD; van Rooijen EM; May AM; Koffijberg H; van Tinteren H; Mol L; Ten Tije AJ; Creemers GJ; van der Velden AMT; Tanis BC; Uyl-de Groot CA; Punt CJA; Koopman M; van Oijen MGH
Eur J Cancer; 2017 Apr; 75():204-212. PubMed ID: 28237866
[TBL] [Abstract][Full Text] [Related]
12. Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
Shim YB; Oh BC; Lee EK; Park MH
BMC Cancer; 2024 Feb; 24(1):189. PubMed ID: 38336654
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
14. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
15. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
16. Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.
Stella SF; Gehling Bertoldi E; Polanczyk CA
Med Decis Making; 2016 Nov; 36(8):1034-42. PubMed ID: 26964876
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
19. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
